<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medical Inspection - Health Blog &#187; Health</title>
	<atom:link href="http://www.medicalinspection.net/category/health/feed" rel="self" type="application/rss+xml" />
	<link>http://www.medicalinspection.net</link>
	<description></description>
	<lastBuildDate>Thu, 15 Jul 2010 06:06:23 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Antimicrobial Agents and Chemotherapy: Combination PI-Containing Regimen for HIV-Infected, Treatment-Experienced Patients</title>
		<link>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-combination-pi-containing-regimen-for-hiv-infected-treatment-experienced-patients.html</link>
		<comments>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-combination-pi-containing-regimen-for-hiv-infected-treatment-experienced-patients.html#comments</comments>
		<pubDate>Thu, 15 Jul 2010 06:06:23 +0000</pubDate>
		<dc:creator>Kristina Albers</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antimicrobial Agents]]></category>
		<category><![CDATA[Chemotherapy]]></category>

		<guid isPermaLink="false">http://www.medicalinspection.net/?p=1338</guid>
		<description><![CDATA[
Combination PI-Containing Regimen for HIV-Infected, Treatment-Experienced Patients
Speaker: Robert Schooley, MD, Head of Infectious Diseases and Professor of Medicine, University of Colorado, Denver, Colorado.
Based on a preliminary 24-week analysis, amprenavir 600 mg (Agenerase, GlaxoSmithKline)/ritonavir 100 mg (Norvir drug, Abbott) twice daily might be a better treatment regimen than amprenavir 900 mg/ritonavir 100 mg twice daily because [...]]]></description>
		<wfw:commentRss>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-combination-pi-containing-regimen-for-hiv-infected-treatment-experienced-patients.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Antimicrobial Agents and Chemotherapy: Recombinant Protein for Severe Sepsis</title>
		<link>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-recombinant-protein-for-severe-sepsis.html</link>
		<comments>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-recombinant-protein-for-severe-sepsis.html#comments</comments>
		<pubDate>Wed, 14 Jul 2010 06:06:22 +0000</pubDate>
		<dc:creator>Kristina Albers</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antimicrobial Agents]]></category>
		<category><![CDATA[Chemotherapy]]></category>

		<guid isPermaLink="false">http://www.medicalinspection.net/?p=1337</guid>
		<description><![CDATA[Speaker: Steven P. LaRosa, MD, Associate Staff Physician, Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, Ohio.
Drotreogin alfa activated (Xigris, Lilly), a recombinant form of protein C recently approved by the FDA for the treatment of severe sepsis, markedly reduces the risk of all-cause mortality in adult patients, according to findings from the PROWESS (Recombinant [...]]]></description>
		<wfw:commentRss>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-recombinant-protein-for-severe-sepsis.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Antimicrobial Agents and Chemotherapy: Potent Antibiotic Combination for Resistant S. aureus Bacteremias</title>
		<link>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-potent-antibiotic-combination-for-resistant-s-aureus-bacteremias.html</link>
		<comments>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-potent-antibiotic-combination-for-resistant-s-aureus-bacteremias.html#comments</comments>
		<pubDate>Tue, 13 Jul 2010 06:06:20 +0000</pubDate>
		<dc:creator>Kristina Albers</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antimicrobial Agents]]></category>
		<category><![CDATA[Chemotherapy]]></category>

		<guid isPermaLink="false">http://www.medicalinspection.net/?p=1336</guid>
		<description><![CDATA[Speaker: Joseph L. Gugliotta, MD, Infectious Disease Specialist, Hunterdon Medical Center, Flemington, New Jersey.
The combination of quinupristin/dalfopristin (Synercid, Aventis) and vancomycin (Vancocin, Lilly) proved to be highly effective in the treatment of bacteremias caused by oxacillin-resistant Staphylococcus aureus (ORSA) strains, demonstrating enhanced bactericidal activity compared with either antibiotic tested alone.
Two patients with oxacillin-resistant S. aureus [...]]]></description>
		<wfw:commentRss>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy-potent-antibiotic-combination-for-resistant-s-aureus-bacteremias.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Antimicrobial Agents and Chemotherapy</title>
		<link>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy.html</link>
		<comments>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy.html#comments</comments>
		<pubDate>Mon, 12 Jul 2010 06:06:19 +0000</pubDate>
		<dc:creator>Kristina Albers</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antimicrobial Agents]]></category>
		<category><![CDATA[Chemotherapy]]></category>

		<guid isPermaLink="false">http://www.medicalinspection.net/?p=1335</guid>
		<description><![CDATA[Short-Duration Antimicrobial Therapy for AECB
Speaker: Marcus J. Zervos, MD, Clinical Professor of Medicine, Wayne State University School of Medicine, Detroit, Michigan, and William Beaumont Hospital, Royal Oak, Michigan.
Five-day therapy with oral telithromycin (Ketek, Aventis), a new ketolide antimicrobial agent, is as effective as standard 10-day treatment with comparators in adult patients with acute exacerbation of [...]]]></description>
		<wfw:commentRss>http://www.medicalinspection.net/antimicrobial-agents-and-chemotherapy.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How the Delayed Distribution: DISCUSSION AND POSSIBLE NEXT STEPS</title>
		<link>http://www.medicalinspection.net/how-the-delayed-distribution-discussion-and-possible-next-steps.html</link>
		<comments>http://www.medicalinspection.net/how-the-delayed-distribution-discussion-and-possible-next-steps.html#comments</comments>
		<pubDate>Sat, 10 Jul 2010 10:03:43 +0000</pubDate>
		<dc:creator>Kristina Albers</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CRITICAL COMPONENTS]]></category>
		<category><![CDATA[Delayed Distribution]]></category>
		<category><![CDATA[Influenza Vaccine]]></category>

		<guid isPermaLink="false">http://www.medicalinspection.net/?p=1313</guid>
		<description><![CDATA[
Several points related to the recent influenza vaccine delays and the influenza vaccine process are worth emphasizing. First, the overall process has worked well for decades despite its many complexities and &#8220;fragilities.&#8221; Although the recent delays highlight the need to take certain actions to strengthen the system, such major disruptions have been exceptional and the [...]]]></description>
		<wfw:commentRss>http://www.medicalinspection.net/how-the-delayed-distribution-discussion-and-possible-next-steps.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How the Delayed Distribution: CRITICAL COMPONENTS OF THE INFLUENZA VACCINE PROCESS</title>
		<link>http://www.medicalinspection.net/how-the-delayed-distribution-critical-components-of-the-influenza-vaccine-process.html</link>
		<comments>http://www.medicalinspection.net/how-the-delayed-distribution-critical-components-of-the-influenza-vaccine-process.html#comments</comments>
		<pubDate>Fri, 09 Jul 2010 10:03:42 +0000</pubDate>
		<dc:creator>Kristina Albers</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CRITICAL COMPONENTS]]></category>
		<category><![CDATA[Delayed Distribution]]></category>
		<category><![CDATA[Influenza Vaccine]]></category>

		<guid isPermaLink="false">http://www.medicalinspection.net/?p=1312</guid>
		<description><![CDATA[The public and private sectors both play extensive and critical roles in the influenza vaccine process. Primary responsibilities of the public sector include monitoring changes among circulating influenza viruses, annually updating the vaccine strains, monitoring the vaccine&#8217;s effectiveness and coverage rates, and developing recommendations to guide vaccine use. Primary responsibilities of the private sector include [...]]]></description>
		<wfw:commentRss>http://www.medicalinspection.net/how-the-delayed-distribution-critical-components-of-the-influenza-vaccine-process.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How the Delayed Distribution: Recent Patterns in Influenza Vaccine Production and Distribution</title>
		<link>http://www.medicalinspection.net/how-the-delayed-distribution-recent-patterns-in-influenza-vaccine-production-and-distribution.html</link>
		<comments>http://www.medicalinspection.net/how-the-delayed-distribution-recent-patterns-in-influenza-vaccine-production-and-distribution.html#comments</comments>
		<pubDate>Thu, 08 Jul 2010 10:03:41 +0000</pubDate>
		<dc:creator>Kristina Albers</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CRITICAL COMPONENTS]]></category>
		<category><![CDATA[Delayed Distribution]]></category>
		<category><![CDATA[Influenza Vaccine]]></category>

		<guid isPermaLink="false">http://www.medicalinspection.net/?p=1311</guid>
		<description><![CDATA[
Among the current manufacturers, Aventis Pasteur and Wyeth Lederle produce influenza vaccine in manufacturing plants located in the U.S. while Evans Vaccines produces influenza vaccine in the United Kingdom, but distributes a percentage of their production in the U.S. In most years, more doses of influenza vaccine are produced by manufacturers, and are released by [...]]]></description>
		<wfw:commentRss>http://www.medicalinspection.net/how-the-delayed-distribution-recent-patterns-in-influenza-vaccine-production-and-distribution.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
